Newly published findings from the international ASPirin in Reducing Events in the Elderly (ASPREE) trial suggest that daily low-dose aspirin does not prolong healthy living in older adults.
The randomised, double-blind, placebo-controlled trial enrolled 19,114 older people who were followed for an average of 4.7 years. Participants were randomly assigned to receive 100mg of enteric-coated aspirin or placebo.
The trial found the use of low-dose aspirin did not prolong disability-free survival among elderly participants over a period of five years. Aspirin was also associated with significantly higher risk of major haemorrhage and did not result in a significantly lower risk of cardiovascular disease than placebo.
Furthermore, the authors identified higher all-cause mortality among apparently healthy older adults who received daily aspirin than among those who received placebo. The increase in mortality was attributed primarily to cancer-related death.
They pointed out that other primary prevention trials of aspirin have not identified a similar result and said the mortality results reported here should be interpreted with caution.
The findings are published in three separate studies in the New England Journal of Medicine.